MediSix Therapeutics Signs Exclusive Licensing Agreement with the National University of Singapore – Markets Insider
|
MediSix Therapeutics Signs Exclusive Licensing Agreement with the National University of Singapore
Markets Insider Lightstone Singapore, L.P. and Professor Dario Campana from the Department of Pediatrics, NUS Yong Loo Lin School of Medicine founded MediSix in 2016 to develop novel Chimeric Antigen Receptor (CAR) T-cell immunotherapies. Through this licensing … |
